{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T03:57:03Z","timestamp":1779163023734,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2024YFC2310700"],"award-info":[{"award-number":["2024YFC2310700"]}]},{"name":"Sichuan Science and Technology Program","award":["2023ZYD0169"],"award-info":[{"award-number":["2023ZYD0169"]}]},{"name":"West China Hospital of Sichuan University","award":["ZYGD23038"],"award-info":[{"award-number":["ZYGD23038"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The rapid and ongoing emergence of SARS-CoV-2 variants has progressively reduced the protection offered by current vaccines, underscoring the urgent need for novel vaccine strategies. In this study, we designed a two-component vaccine in which one component is an adenoviral vector encoding the Omicron XBB.1.5 spike protein (Ad5\n                    <jats:sub>XBB.1.5<\/jats:sub>\n                    ), and the other component is a self-assembling trimeric receptor-binding domain protein (RBD\n                    <jats:sub>XBB.1.5<\/jats:sub>\n                    -HR or RBD\n                    <jats:sub>JN.1<\/jats:sub>\n                    -HR). This platform integrates the complementary advantages of subunit protein and adenoviral vector vaccines, elicits robust humoral and cellular immunity in mice after intramuscular administration. Durable IgG responses induced by this two-component vaccine were maintained for over six months post-immunization in mice, attributed to their ability to generate memory B cells and long-lived plasma cells responses. Furthermore, in a heterologous booster setting following mRNA (mRNA\n                    <jats:sub>BA.4<\/jats:sub>\n                    and mRNA\n                    <jats:sub>XBB.1.5<\/jats:sub>\n                    ) priming, the two-component vaccine can be severed as a boost shot to rescue the neutralization against emerging variants, such as JN.1. These findings indicate that the two-component vaccine system can act effectively on its own and also serve as a heterologous booster that enhances protection against antigenically evolved variants. Furthermore, the modularity of this platform suggests broad applicability for rapid adaptation to future SARS-CoV-2 strains and for vaccine development against other fast-evolving respiratory viruses. Collectively, this study provides a generalizable framework for next-generation COVID-19 vaccine design and supports the translational relevance of two-component vaccines in the context of continual viral diversification.\n                  <\/jats:p>","DOI":"10.1186\/s43556-026-00410-x","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:49:11Z","timestamp":1773323351000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combination of adenovirus vector and subunit protein elicits a robust immune response against the SARS-CoV-2 Omicron variant"],"prefix":"10.1186","volume":"7","author":[{"given":"Chunjun","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiya","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danyi","family":"Ao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yishan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingqiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiruo","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangwen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangrong","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6513-6422","authenticated-orcid":false,"given":"Xiawei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"410_CR1","unstructured":"WHO. WHO COVID-19 dashboard. Periodical WHO COVID-19 dashboard 2024."},{"issue":"1","key":"410_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/s1473-3099(22)00816-7","volume":"23","author":"R Uraki","year":"2023","unstructured":"Uraki R, Ito M, Furusawa Y, Yamayoshi S, Iwatsuki-Horimoto K, Adachi E, et al. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect Dis. 2023;23(1):30\u20132. https:\/\/doi.org\/10.1016\/s1473-3099(22)00816-7.","journal-title":"Lancet Infect Dis"},{"key":"410_CR3","doi-asserted-by":"publisher","unstructured":"Kurhade C, Zou J, Xia HJ, Liu MR, Chang H, Ren P et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med. 2023;29(2):13. https:\/\/doi.org\/10.1038\/s41591-022-02162-x.","DOI":"10.1038\/s41591-022-02162-x"},{"issue":"4","key":"410_CR4","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/s1473-3099(23)00070-1","volume":"23","author":"R Uraki","year":"2023","unstructured":"Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Furusawa Y, et al. Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate. Lancet Infect Dis. 2023;23(4):402\u20133. https:\/\/doi.org\/10.1016\/s1473-3099(23)00070-1.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"410_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/s1473-3099(23)00010-5","volume":"23","author":"C Yue","year":"2023","unstructured":"Yue C, Song WL, Wang L, Jian FC, Chen XS, Gao F, et al. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. Lancet Infect Dis. 2023;23(3):278\u201380. https:\/\/doi.org\/10.1016\/s1473-3099(23)00010-5.","journal-title":"Lancet Infect Dis"},{"key":"410_CR6","doi-asserted-by":"publisher","unstructured":"Qu PK, Faraone JN, Evans JP, Zheng YM, Carlin C, Anghelina M et al. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants. Cell Reports. 2023;42(5):15. https:\/\/doi.org\/10.1016\/j.celrep.2023.112443.","DOI":"10.1016\/j.celrep.2023.112443"},{"key":"410_CR7","doi-asserted-by":"publisher","unstructured":"Wang Q, Lekthan S, Li ZT, Liu LY, Guo YC, Huang YM et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186(2):279-+. https:\/\/doi.org\/10.1016\/j.cell.2022.12.018.","DOI":"10.1016\/j.cell.2022.12.018"},{"issue":"3","key":"410_CR8","doi-asserted-by":"publisher","first-page":"E131","DOI":"10.1016\/s2666-5247(22)00335-4","volume":"4","author":"XJ Zhang","year":"2023","unstructured":"Zhang XJ, Chen LL, Ip JD, Chan WM, Hung IFN, Yuen KY, et al. Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines. Lancet Microbe. 2023;4(3):E131-E. https:\/\/doi.org\/10.1016\/s2666-5247(22)00335-4.","journal-title":"Lancet Microbe"},{"key":"410_CR9","doi-asserted-by":"crossref","unstructured":"Yue C, Song W, Wang L, Jian F, Chen X, Gao F et al. Enhanced transmissibility of XBB. 1.5 is contributed by both strong ACE2 binding and antibody evasion. 2023:2023.01. 03.522427.","DOI":"10.1101\/2023.01.03.522427"},{"issue":"5","key":"410_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101049","volume":"4","author":"JN Faraone","year":"2023","unstructured":"Faraone JN, Qu PK, Evans JP, Zheng YM, Carlin C, Anghelina M, et al. Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants. Cell Rep Med. 2023;4(5):10. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101049.","journal-title":"Cell Rep Med"},{"issue":"4","key":"410_CR11","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/s1473-3099(25)00113-6","volume":"25","author":"L Zhang","year":"2025","unstructured":"Zhang L, Kempf A, Nehlmeier I, Chen N, Stankov MV, Happle C, et al. Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1. Lancet Infect Dis. 2025;25(4):e196\u20137. https:\/\/doi.org\/10.1016\/s1473-3099(25)00113-6.","journal-title":"Lancet Infect Dis"},{"key":"410_CR12","unstructured":"WHO. SARS-CoV-2 variant circulation: 05 October to 02 November 2025. Periodical SARS-CoV-2 variant circulation: 05 October to 02 November 2025."},{"issue":"6483","key":"410_CR13","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp D, Wang NS, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260. https:\/\/doi.org\/10.1126\/science.abb2507.","journal-title":"Science"},{"key":"410_CR14","doi-asserted-by":"publisher","unstructured":"Yang JY, Wang W, Chen ZM, Lu SY, Yang FL, Bi ZF et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity (vol 586, pg 572, 2020). Nature. 2021:1. https:\/\/doi.org\/10.1038\/s41586-020-03108-4.","DOI":"10.1038\/s41586-020-03108-4"},{"issue":"1","key":"410_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33209-9","volume":"13","author":"C He","year":"2022","unstructured":"He C, Yang J, Hong W, Chen Z, Peng D, Lei H, et al. A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant. Nat Commun. 2022;13(1):5459. https:\/\/doi.org\/10.1038\/s41467-022-33209-9.","journal-title":"Nat Commun"},{"issue":"1","key":"410_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55087-z","volume":"15","author":"J Yang","year":"2024","unstructured":"Yang J, Hong W, Shi H, He C, Lei H, Zhou Y, et al. Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials. Nat Commun. 2024;15(1):10778. https:\/\/doi.org\/10.1038\/s41467-024-55087-z.","journal-title":"Nat Commun"},{"issue":"S1","key":"410_CR17","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1002\/jgm.496","volume":"6","author":"C Volpers","year":"2004","unstructured":"Volpers C, Kochanek SJ. Adenoviral vectors for gene transfer and therapy. J Gene Med. 2004;6(S1):S164\u201371.","journal-title":"J Gene Med"},{"issue":"6","key":"410_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/1566523213666131125095046","volume":"13","author":"WSM Wold","year":"2013","unstructured":"Wold WSM, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013;13(6):421\u201333.","journal-title":"Curr Gene Ther"},{"issue":"10240","key":"410_CR19","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/s0140-6736(20)31208-3","volume":"395","author":"FC Zhu","year":"2020","unstructured":"Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845\u201354. https:\/\/doi.org\/10.1016\/s0140-6736(20)31208-3.","journal-title":"Lancet"},{"issue":"10269","key":"410_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99\u2013111. https:\/\/doi.org\/10.1016\/s0140-6736(20)32661-1.","journal-title":"Lancet"},{"issue":"7","key":"410_CR21","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/s2213-2600(23)00049-8","volume":"11","author":"R Tang","year":"2023","unstructured":"Tang R, Zheng H, Wang BS, Gou JB, Guo XL, Chen XQ, et al. Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial. Lancet Respir Med. 2023;11(7):613\u201323. https:\/\/doi.org\/10.1016\/s2213-2600(23)00049-8.","journal-title":"Lancet Respir Med"},{"issue":"23","key":"410_CR22","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, Gray G, Vandebosch A, C\u00e1rdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187\u2013201. https:\/\/doi.org\/10.1056\/NEJMoa2101544.","journal-title":"N Engl J Med"},{"issue":"10269","key":"410_CR23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(20)32721-5","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov DY, Dolzhikova IV, Zubkova OV. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia (vol 396, pg 887, 2020). Lancet. 2021;397(10269):98.","journal-title":"Lancet"},{"issue":"4","key":"410_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1556\/EuJMI.1.2011.4.3","volume":"1","author":"G Fejer","year":"2011","unstructured":"Fejer G, Freudenberg M, Greber UF, Gyory I. Adenovirus-triggered innate signalling pathways. Eur J Microbiol Immunol (Bp). 2011;1(4):279\u201388. https:\/\/doi.org\/10.1556\/EuJMI.1.2011.4.3.","journal-title":"Eur J Microbiol Immunol (Bp)"},{"issue":"1","key":"410_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1146\/annurev-virology-092818-015550","volume":"6","author":"UF Greber","year":"2019","unstructured":"Greber UF, Flatt JW. Adenovirus entry: from infection to immunity. Annu Rev Virol. 2019;6(1):177\u201397. https:\/\/doi.org\/10.1146\/annurev-virology-092818-015550.","journal-title":"Annu Rev Virol"},{"issue":"5824","key":"410_CR26","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1126\/science.1137971","volume":"316","author":"S Burgdorf","year":"2007","unstructured":"Burgdorf S, Kautz A, B\u00f6hnert V, Knolle PA, Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science. 2007;316(5824):612\u20136. https:\/\/doi.org\/10.1126\/science.1137971.","journal-title":"Science"},{"issue":"3","key":"410_CR27","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1172\/jci78280","volume":"125","author":"KM Quinn","year":"2015","unstructured":"Quinn KM, Zak DE, Costa A, Yamamoto A, Kastenmuller K, Hill BJ, et al. Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. J Clin Invest. 2015;125(3):1129\u201346. https:\/\/doi.org\/10.1172\/jci78280.","journal-title":"J Clin Invest"},{"issue":"1","key":"410_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00637-7","volume":"8","author":"E Saeland","year":"2023","unstructured":"Saeland E, van der Fits L, Bolder R, van der Heemskerk- Meer M, Drijver J, van Polanen Y, et al. Combination Ad26.RSV.preF\/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models. NPJ Vaccines. 2023;8(1):13. https:\/\/doi.org\/10.1038\/s41541-023-00637-7.","journal-title":"NPJ Vaccines"},{"key":"410_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01517-2","author":"W Hong","year":"2025","unstructured":"Hong W, Cheng P, Yang J, Shi H, Wang Z, Li J, et al. Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant. Nat Biomed Eng. 2025. https:\/\/doi.org\/10.1038\/s41551-025-01517-2.","journal-title":"Nat Biomed Eng"},{"issue":"7830","key":"410_CR30","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","volume":"586","author":"J Yang","year":"2020","unstructured":"Yang J, Wang W, Chen Z, Lu S, Yang F, Bi Z, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020;586(7830):572\u20137. https:\/\/doi.org\/10.1038\/s41586-020-2599-8.","journal-title":"Nature"},{"issue":"4","key":"410_CR31","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","volume":"184","author":"A Sette","year":"2021","unstructured":"Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861\u201380. https:\/\/doi.org\/10.1016\/j.cell.2021.01.007.","journal-title":"Cell"},{"key":"410_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1146\/annurev-immunol-101721-061120","volume":"41","author":"A Sette","year":"2023","unstructured":"Sette A, Sidney J, Crotty S. T cell responses to SARS-CoV-2. Annu Rev Immunol. 2023;41:343\u201373. https:\/\/doi.org\/10.1146\/annurev-immunol-101721-061120.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"410_CR33","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.immuni.2016.09.001","volume":"45","author":"L Mesin","year":"2016","unstructured":"Mesin L, Ersching J, Victora GD. Germinal center B cell dynamics. Immunity. 2016;45(3):471\u201382. https:\/\/doi.org\/10.1016\/j.immuni.2016.09.001.","journal-title":"Immunity"},{"issue":"3","key":"410_CR34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nri3795","volume":"15","author":"SL Nutt","year":"2015","unstructured":"Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015;15(3):160\u201371. https:\/\/doi.org\/10.1038\/nri3795.","journal-title":"Nat Rev Immunol"},{"key":"410_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.821729","volume":"12","author":"M Broketa","year":"2021","unstructured":"Broketa M, Bruhns P. Single-cell technologies for the study of antibody-secreting cells. Front Immunol. 2021;12:821729. https:\/\/doi.org\/10.3389\/fimmu.2021.821729.","journal-title":"Front Immunol"},{"issue":"6","key":"410_CR36","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.immuni.2020.11.006","volume":"53","author":"RA Elsner","year":"2020","unstructured":"Elsner RA, Shlomchik MJ. Germinal center and extrafollicular B cell responses in vaccination, immunity, and autoimmunity. Immunity. 2020;53(6):1136\u201350. https:\/\/doi.org\/10.1016\/j.immuni.2020.11.006.","journal-title":"Immunity"},{"issue":"6","key":"410_CR37","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1042\/bst20220415","volume":"50","author":"HA Fryer","year":"2022","unstructured":"Fryer HA, Hartley GE, Edwards ESJ, O\u2019Hehir RE, van Zelm MC. Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. Biochem Soc Trans. 2022;50(6):1643\u201358. https:\/\/doi.org\/10.1042\/bst20220415.","journal-title":"Biochem Soc Trans"},{"issue":"4","key":"410_CR38","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.immuni.2010.10.008","volume":"33","author":"F Sallusto","year":"2010","unstructured":"Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity. 2010;33(4):451\u201363. https:\/\/doi.org\/10.1016\/j.immuni.2010.10.008.","journal-title":"Immunity"},{"key":"410_CR39","doi-asserted-by":"crossref","unstructured":"Greber UF, Flatt JW. Adenovirus Entry: From Infection to Immunity. In: Enquist L, DiMaio D, Demody T, editors. Annual Review of Virology, Vol 6, 2019. Annual Review of Virology. Palo Alto: Annual Reviews; 2019. p. 177\u201397.","DOI":"10.1146\/annurev-virology-092818-015550"},{"issue":"6","key":"410_CR40","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1128\/jvi.76.6.2667-2675.2002","volume":"76","author":"ZQ Xiang","year":"2002","unstructured":"Xiang ZQ, Gao GP, Reyes-Sandoval A, Cohen CJ, Li Y, Bergelson JM, et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol. 2002;76(6):2667\u201375. https:\/\/doi.org\/10.1128\/jvi.76.6.2667-2675.2002.","journal-title":"J Virol"},{"issue":"1","key":"410_CR41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1084\/jem.20072681","volume":"205","author":"RP Sekaly","year":"2008","unstructured":"Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med. 2008;205(1):7\u201312. https:\/\/doi.org\/10.1084\/jem.20072681.","journal-title":"J Exp Med"},{"issue":"10249","key":"410_CR42","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","volume":"396","author":"F-C Zhu","year":"2020","unstructured":"Zhu F-C, Guan X-H, Li Y-H, Huang J-Y, Jiang T, Hou L-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479\u201388.","journal-title":"Lancet"},{"issue":"6313","key":"410_CR43","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1126\/science.aag1322","volume":"354","author":"KM Gostic","year":"2016","unstructured":"Gostic KM, Ambrose M, Worobey M, Lloyd-Smith JO. Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science. 2016;354(6313):722\u20136. https:\/\/doi.org\/10.1126\/science.aag1322.","journal-title":"Science"},{"issue":"1","key":"410_CR44","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","volume":"7","author":"E Fang","year":"2022","unstructured":"Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B, et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther. 2022;7(1):94.","journal-title":"Signal Transduct Target Ther"},{"key":"410_CR45","doi-asserted-by":"publisher","unstructured":"Wang Q, Guo Y, Bowen A, Mellis IA, Valdez R, Gherasim C et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe. 2024;32(3):315\u201321.e3. https:\/\/doi.org\/10.1016\/j.chom.2024.01.014.","DOI":"10.1016\/j.chom.2024.01.014"},{"key":"410_CR46","unstructured":"Leaf-nosed bat. Encyclop\u00e6dia Britannica: Encyclop\u00e6dia Britannica Online; 2009."},{"issue":"8","key":"410_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70301","volume":"6","author":"J Shi","year":"2025","unstructured":"Shi J, Lei H, Zhang Y, Ye C, Huang X, Lu Y, et al. Combining intramuscular and intranasal immunization with the MF59-adjuvanted respiratory syncytial virus pre-fusion protein subunit vaccine induces potent humoral and cellular immune responses in mice. MedComm. 2025;6(8):e70301. https:\/\/doi.org\/10.1002\/mco2.70301.","journal-title":"MedComm"},{"issue":"1","key":"410_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02025-6","volume":"9","author":"H Lei","year":"2024","unstructured":"Lei H, Hong W, Yang J, He C, Zhou Y, Zhang Y, et al. Intranasal delivery of a subunit protein vaccine provides protective immunity against JN.1 and XBB-lineage variants. Signal Transduct Target Ther. 2024;9(1):311. https:\/\/doi.org\/10.1038\/s41392-024-02025-6.","journal-title":"Signal Transduct Target Ther"},{"key":"410_CR49","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jconrel.2021.05.024","volume":"335","author":"H Huang","year":"2021","unstructured":"Huang H, Zhang CL, Yang SP, Xiao W, Zheng Q, Song XR. The investigation of mRNA vaccines formulated in liposomes administrated in multiple routes against SARS-CoV-2. J Control Release. 2021;335:449\u201356. https:\/\/doi.org\/10.1016\/j.jconrel.2021.05.024.","journal-title":"J Control Release"},{"issue":"1","key":"410_CR50","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","volume":"183","author":"AO Hassan","year":"2020","unstructured":"Hassan AO, Kafai NM, Dmitriev IP, Fox JM, Smith BK, Harvey IB, et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell. 2020;183(1):169. https:\/\/doi.org\/10.1016\/j.cell.2020.08.026.","journal-title":"Cell"},{"issue":"1","key":"410_CR51","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41467-022-33209-9","volume":"13","author":"C He","year":"2022","unstructured":"He C, Yang JY, Hong WQ, Chen ZM, Peng DD, Lei H, et al. A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant. Nat Commun. 2022;13(1):14. https:\/\/doi.org\/10.1038\/s41467-022-33209-9.","journal-title":"Nat Commun"},{"issue":"1","key":"410_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38066-8","volume":"14","author":"H Lei","year":"2023","unstructured":"Lei H, Alu A, Yang J, He X, He C, Ren W, et al. Cationic crosslinked carbon dots-adjuvanted intranasal vaccine induces protective immunity against Omicron-included SARS-CoV-2 variants. Nat Commun. 2023;14(1):2678. https:\/\/doi.org\/10.1038\/s41467-023-38066-8.","journal-title":"Nat Commun"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00410-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00410-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00410-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:49:18Z","timestamp":1773323358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00410-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["410"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00410-x","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments in this study were approved by the Institutional Animal Care and Use Committee of Sichuan University (ethical approval number: 20230227017).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}